Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
2.190
+0.090 (4.29%)
Sep 20, 2024, 4:00 PM EDT - Market closed
Pulmatrix Revenue
Pulmatrix had revenue of $1.55M in the quarter ending June 30, 2024, a decrease of -15.84%. This brings the company's revenue in the last twelve months to $11.39M, up 64.55% year-over-year. In the year 2023, Pulmatrix had annual revenue of $7.30M with 20.21% growth.
Revenue (ttm)
$11.39M
Revenue Growth
+64.55%
P/S Ratio
0.70
Revenue / Employee
$517,818
Employees
22
Market Cap
8.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 7.30M | 1.23M | 20.21% |
Dec 31, 2022 | 6.07M | 902.00K | 17.45% |
Dec 31, 2021 | 5.17M | -7.47M | -59.09% |
Dec 31, 2020 | 12.63M | 4.72M | 59.72% |
Dec 31, 2019 | 7.91M | 7.76M | 5,069.93% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Syra Health | 7.07M |
NeuroMetrix | 4.38M |
Addex Therapeutics | 1.53M |
TFF Pharmaceuticals | 1.20M |
Mangoceuticals | 866.79K |
Soligenix | 494.62K |
Traws Pharma | 226.00K |
ABVC BioPharma | 136.40K |
PULM News
- 5 weeks ago - Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - PRNewsWire
- 4 months ago - Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - PRNewsWire
- 4 months ago - Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 6 months ago - Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 9 months ago - Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives - PRNewsWire
- 11 months ago - Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 1 year ago - Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine - PRNewsWire